筹划重大资产重组！向日葵，明起停牌

Core Viewpoint - Company is planning to acquire controlling stakes in Zhangzhou Xipu Material Technology Co., Ltd. and 40% stake in Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment, which is expected to constitute a major asset restructuring [1][2] Group 1: Acquisition Details - The company has signed a letter of intent with the major shareholder of Xipu Material, Shanghai Xipu Technology Co., Ltd., to acquire its controlling stake [2] - The company also signed an agreement with Shaoxing Xiangri Investment Co., Ltd., the shareholder of Beid Pharmaceutical, to acquire 40% of its shares [2] - The agreements are preliminary intentions, and the specific transaction details will be formalized in subsequent agreements [2] Group 2: Related Transactions - The transaction with Beid Pharmaceutical is considered a related party transaction as it involves a company controlled by the actual controller of the company, Wu Jianlong [2] - The transaction is not expected to change the actual controller of the company and does not constitute a restructuring listing [2] Group 3: Company Performance - In the first half of the year, the company reported revenue of approximately 144 million yuan, a year-on-year decrease of 8.33% [4] - The net profit attributable to the parent company was approximately 1.16 million yuan, down 35.68% year-on-year [4] - The decline in performance is attributed to reduced sales profits, changes in period expenses, and increased inventory impairment provisions [4] Group 4: Market Activity - On September 5, the company's stock price increased by 11.96%, closing at 4.96 yuan per share, with a total market capitalization of 6.38 billion yuan [5]